Kowal Investment Group LLC purchased a new stake in Bristol-Myers Squibb (NYSE: BMY – Get Rating) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 3,021 shares of the biopharmaceutical company stock, valued at approximately $ 221,000.
Several other hedge funds and other institutional investors have also made changes to their positions in BMY. Mizuho Securities Co. Ltd. lifted its holdings in shares of Bristol-Myers Squibb by 239.0% in the first quarter. Mizuho Securities Co. Ltd. now owns 339 shares of the biopharmaceutical company stock valued at $ 25,000 after purchasing an additional 239 shares in the last quarter. Steward Financial Group LLC purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $ 29,000. Horan Securities Inc. purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $ 29,000. Guardian Wealth Management Inc. purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $ 32,000. Finally, Leverty Financial Group LLC acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $ 37,000. 73.07% of the stock is currently owned by institutional investors.
In other news, CEO Giovanni Caforio sold 30,000 shares of the company stock in a transaction on Monday, June 13th. The shares were sold at an average price of $ 74.04, for a total value of $ 2,221,200.00. Following the completion of the transaction, the chief executive officer now directly owns 551,104 shares in the company, valued at $ 40,803,740.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sandra Leung sold 65,000 shares of the company stock in a transaction on Monday, June 6th. The shares were sold at an average price of $ 74.89, for a total transaction of $ 4,867,850.00. Following the completion of the transaction, the executive vice president now owns 308,627 shares of the company stock, valued at $ 23,113,076.03. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.
BMY opened at $ 78.96 on Friday. The company has a quick ratio of 1.23, a current ratio of 1.32 and a debt-to-equity ratio of 1.18. Bristol-Myers Squibb has a 52-week low of $ 53.22 and a 52-week high of $ 79.00. The company has a 50 day moving average of $ 75.96 and a two-hundred day moving average of $ 70.21. The company has a market cap of $ 168.11 billion, a P / E ratio of 28.00, a P / E / G ratio of 1.67 and a beta of 0.49.
Bristol-Myers Squibb (NYSE: BMY – Get Rating) last released its quarterly earnings data on Friday, April 29th. The biopharmaceutical company reported $ 1.96 earnings per share (EPS) for the quarter, topping the estimate consensus of $ 1.92 by $ 0.04. Bristol-Myers Squibb had a net margin of 13.31% and a return on equity of 48.37%. The company had revenue of $ 11.65 billion during the quarter, compared to the estimate consensus of $ 11.34 billion. During the same period in the previous year, the firm earned $ 1.74 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 5.2% on a year-over-year basis. Research analysts anticipate that Bristol-Myers Squibb will post 7.56 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 1st. Shareholders of record on Friday, July 1st will be paid a dividend of $ 0.54 per share. The ex-dividend date of this dividend is Thursday, June 30th. This represents a $ 2.16 annualized dividend and a yield of 2.74%. Bristol-Myers Squibb’s dividend payout ratio is currently 76.60%.
A number of equities analysts have recently weighed in on the stock. Morgan Stanley cut their price objective on shares of Bristol-Myers Squibb from $ 66.00 to $ 64.00 and set an “underweight” rating for the company in a research report on Wednesday, April 6th. Bank of America boosted their price objective on shares of Bristol-Myers Squibb from $ 78.00 to $ 80.00 and gave the company a “buy” rating in a research report on Monday, June 6th. Guggenheim boosted their price objective on shares of Bristol-Myers Squibb from $ 72.00 to $ 80.00 in a research report on Monday, May 2nd. Raymond James lowered shares of Bristol-Myers Squibb from an “outperform” rating to a “market perform” rating in a research report on Friday, June 3rd. They noted that the move was a valuation call. Finally, Citigroup reissued a “buy” rating and issued a $ 90.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, June 3rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company stock. According to MarketBeat.com, Bristol-Myers Squibb presently has an average rating of “Moderate Buy” and an average price target of $ 74.27.
About Bristol-Myers Squibb: (Get Rating)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke / systemic embolism in NVAF, and for the treatment of DVT / PE; Opdivo for anti-cancer indications; Pomalyst / Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE: BMY – Get Rating).
Receive News & Ratings for Bristol-Myers Squibb Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.